🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  2. Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml

    Disc Medicine

    Non-psychotic therapy resistant unipolar depression

    phase 3 small molecule active

    1 trial

  3. Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe., COLCHICINE OPOCALCIUM 1 mg, comprimé sécable

    Pari Pharma GmbH

    Familial Mediterranean Fever (FMF)

    phase 3 small molecule active

    1 trial

  4. Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe., Privigen 100 mg/ml solution for infusion

    Pari Pharma GmbH

    Kawasaki disease

    phase 3 small molecule active

    1 trial

  5. Kreon 35 000 Ph. Eur. Lipase Einheiten, magensaftresistente Hartkapseln

    Lacuna Pharma Pty Ltd

    Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).

    phase 3 small molecule active

    1 trial

  6. Kyprolis 60 mg powder for solution for infusion, Kyprolis 30 mg powder for solution for infusion, DARZALEX 1800 mg solution for injection, ENDOXAN omhulde tablet, omhulde tabletten, 50 mg, Cesnicabtagene autoleucel, Kyprolis 10 mg powder for solution for infusion, Dexamethason Teva 4 mg, tabletten, Bortezomib Accord 3.5 mg powder for solution for injection, Empliciti 300 mg powder for concentrate for solution for infusion., Dexamethason Activase 2 mg tabletten, Pomalidomide Accord 4 mg hard capsules, Emplic

    Disc Medicine

    relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  7. LAMIVUDINE AND DOLUTEGRAVIR , DARUNAVIR , DORAVIRINE , DARUNAVIR AND COBICISTAT , EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT, TENOFOVIR ALAFENAMIDE , RITONAVIR , ISLATRAVIR/LENACAPAVIR, LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR AND COBICISTAT, EMTRICITABINE, RALTEGRAVIR , EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, EMTRICITABINE, TENOFOVIR DISOPROXIL AND RILPIVIRINE, DOLUTEGRAVIR , LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE,

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  8. LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE

    Alphapharm Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  9. LB-102

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    4 trials

  10. LB-102 (50 mg tablet)

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  11. LC-1000

    Hospital Authority, Hong Kong

    Coronary Artery Disease

    phase 3 other completed

    1 trial

  12. LECANEMAB

    Eisai Co.,

    Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid

    phase 3 small molecule active

    1 trial

  13. LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CYTARABINE, METHOTREXATE, CYTARABINE, PREDNISONE, METHOTREXATE, Melphalan 50 mg powder and solvent for solution for injection/infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, Idarubicina Sandoz 1 mg/ml concentrato per soluzione per infusione, METHOTREXATE, PREDNISONE, FILGRASTIM, Glivec 100 mg hard capsules, CYTARABINE, PURINETHOL 50 mg compresse, Dexamethasone Phosphate 4 mg/ml Solution for Injection, Keppra 250 mg film-coated tablets, ME

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    phase 3 small molecule active

    1 trial

  14. LETROZOLE, ANASTROZOLE, CAPECITABINE, PACLITAXEL, CAPECITABINE, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Ningbo Cancer Hospital

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 small molecule active

    1 trial

  15. LETROZOLE, Arimidex® 1 mg Filmtabletten, Camizestrant, ABEMACICLIB, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, Nolvadex® 20 mg Filmtabletten, EXEMESTANE

    AstraZeneca AB

    ER+/HER2- Early Breast Cancer

    phase 3 small molecule active

    1 trial

  16. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  17. LETROZOLE, EXEMESTANE, ANASTROZOLE, PALBOCICLIB, FULVESTRANT

    Ningbo Cancer Hospital

    ER+/HER2- metastatic breast cancer

    phase 3 small molecule active

    1 trial

  18. LETROZOLE, IBRANCE 75 mg hard capsules, RIBOCICLIB, ABEMACICLIB, IBRANCE 100 mg hard capsules, ABEMACICLIB, IBRANCE 125 mg hard capsules, ABEMACICLIB

    Pfizer Australia Pty Ltd

    Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  19. LETROZOLE, PALBOCICLIB, Inavolisib placebo, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Letrozol STADA® 2,5 mg Filmtabletten, INAVOLISIB, IBRANCE 100 mg film-coated tablets, INAVOLISIB, RIBOCICLIB, PALBOCICLIB, RIBOCICLIB, PALBOCICLIB

    Hoffmann-La Roche

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  20. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  21. LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, GOSERELIN, EXEMESTANE, RIBOCICLIB

    Novartis Pharmaceuticals

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  22. LEVONOR,1 mg/ml, roztwór do infuzji

    COLLEGIUM PHARMACEUTICAL, INC

    hypotension in non-cardiac surgery

    phase 3 small molecule active

    1 trial

  23. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  24. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources